Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M99,571Revenue (TTM) $M25,242Net Margin (%)24.1Altman Z-Score2.0
Enterprise Value $M128,931EPS (TTM) $3.7Operating Margin %36.2Piotroski F-Score6
P/E(ttm)16.6Beneish M-Score-2.3Pre-tax Margin (%)30.9Higher ROA y-yY
Price/Book15.410-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %0.7Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow14.4y-y EBITDA Growth Rate %94.2ROA % (ttm)10.3Higher Current Ratio y-yN
Dividend Yield %3.8PEG24.0ROE % (ttm)119Less Shares Outstanding y-yY
Payout Ratio %60.0Shares Outstanding M1,625ROIC % (ttm)23.1Gross Margin Increase y-yN

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVKen Fisher 2016-12-31 Add$55.78 - $64
($61.04)
$ 61.381%Add 1.83%696,569
ABBVNWQ Managers 2016-09-30 Reduce-0.44%$61.92 - $67.39
($64.74)
$ 61.38-5%Reduce -73.90%146,743
ABBVJoel Greenblatt 2016-09-30 Reduce-0.16%$61.92 - $67.39
($64.74)
$ 61.38-5%Reduce -24.43%684,356
ABBVDavid Dreman 2016-09-30 Reduce-0.03%$61.92 - $67.39
($64.74)
$ 61.38-5%Reduce -5.52%15,019
ABBVMario Gabelli 2016-09-30 Reduce$61.92 - $67.39
($64.74)
$ 61.38-5%Reduce -42.78%20,196
ABBVKen Fisher 2016-09-30 Reduce$61.92 - $67.39
($64.74)
$ 61.38-5%Reduce -1.35%684,042
ABBVNWQ Managers 2016-06-30 Reduce-0.2%$57.12 - $65.09
($60.87)
$ 61.381%Reduce -28.08%562,288
ABBVJoel Greenblatt 2016-06-30 Add0.19%$57.12 - $65.09
($60.87)
$ 61.381%Add 40.22%905,598
ABBVDavid Dreman 2016-06-30 Reduce-0.1%$57.12 - $65.09
($60.87)
$ 61.381%Reduce -47.95%15,897
ABBVKen Fisher 2016-06-30 Reduce-0.01%$57.12 - $65.09
($60.87)
$ 61.381%Reduce -6.71%693,394
ABBVMario Gabelli 2016-06-30 Reduce$57.12 - $65.09
($60.87)
$ 61.381%Reduce -0.46%35,296
ABBVJoel Greenblatt 2016-03-31 Add0.28%$51.18 - $59.24
($55.77)
$ 61.3810%Add 216.32%645,835
ABBVJohn Paulson 2016-03-31 Sold Out -0.05%$51.18 - $59.24
($55.77)
$ 61.3810%Sold Out0
ABBVDavid Dreman 2016-03-31 Add0.03%$51.18 - $59.24
($55.77)
$ 61.3810%Add 16.28%30,542
ABBVKen Fisher 2016-03-31 Reduce-0.02%$51.18 - $59.24
($55.77)
$ 61.3810%Reduce -20.51%743,284
ABBVNWQ Managers 2016-03-31 Add0.02%$51.18 - $59.24
($55.77)
$ 61.3810%Add 3.64%781,850
ABBVMario Gabelli 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 61.3810%Reduce -12.66%35,460
ABBVDodge & Cox 2016-03-31 Reduce$51.18 - $59.24
($55.77)
$ 61.3810%Reduce -0.07%33,232
ABBVNWQ Managers 2015-12-31 Reduce-0.65%$48.27 - $64.13
($57.69)
$ 61.386%Reduce -50.59%754,413
ABBVFirst Eagle Investment 2015-12-31 Sold Out -0.14%$48.27 - $64.13
($57.69)
$ 61.386%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE WILLIAM JEVP, CFO 2016-12-02Sell6,600$59.194.17view
HURWICH THOMAS A.VP, Controller 2016-11-16Sell3,100$62-0.55view
Schumacher Laura JExecutive Vice President 2016-09-07Sell50,000$65-5.14view
Schumacher Laura JExecutive Vice President 2016-06-24Sell186,106$60.032.72view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-06-02Sell285,953$63.82-3.38view
GONZALEZ RICHARD AChairman of the Board and CEO 2016-05-11Sell39,000$63.8-3.35view
HURWICH THOMAS A.VP, Controller 2016-05-10Sell6,000$63.59-3.04view
RICHMOND TIMOTHY J.SVP, Human Resources 2016-05-10Sell21,583$63.52-2.93view
ALBAN CARLOSEVP, Commercial Operations 2016-05-10Sell47,438$63.52-2.93view
Schumacher Laura JExecutive Vice President 2016-03-08Sell25,000$56.099.93view

Press Releases about ABBV :

Quarterly/Annual Reports about ABBV:

News about ABBV:

Articles On GuruFocus.com
Adient Stock: Still Undervalued After Johnson Controls Spinoff Jan 16 2017 
Entana Pharmaceuticals Releases Results of AbbVie Hepatitis Treatment in Japanese Patients Jan 11 2017 
Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Jan 10 2017 
10 Stocks for Using a Benjamin Graham Value Investing Strategy Jan 10 2017 
The Best DRIP Stocks: 15 No-Fee Dividend Aristocrats Jan 09 2017 
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
Lannet's Lopinavir, Ritonavir Approved to Treat HIV in US Jan 05 2017 
These Biotech Stocks Could Run in 2017 Jan 04 2017 
Discounted Stocks: Apple, Accenture, Aaron's Jan 03 2017 
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 

More From Other Websites
7:03 am AbbVie announces that the FDA has approved IMBRUVICA (ibrutinib) for the treatment of... Jan 19 2017
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for... Jan 19 2017
Orphan Drugs Among 2015's Top 10 Best-Selling Medications Jan 18 2017
[$$] Biotech M&A Deals Expected to Increase in 2017 Jan 17 2017
Adient Stock: Still Undervalued After Johnson Controls Spinoff Jan 16 2017
10 Best Dividend-Paying Stocks for 2017 Jan 13 2017
AbbVie, Inc. – Value Analysis (NYSE:ABBV) : January 13, 2017 Jan 13 2017
Coherus Offers Positive Phase III Data on Humira Biosimilar Jan 13 2017
12 Health Benefits of Medical Marijuana According To Publicly Traded Weed Companies Jan 12 2017
AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : January 12, 2017 Jan 12 2017
Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients Jan 11 2017
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short Jan 11 2017
Emergent Technologies’ Pure MHC Explores A New Collaboration With AbbVie Inc (ABBV) Jan 10 2017
AbbVie to Host Fourth-Quarter 2016 Earnings Conference Call Jan 10 2017
AbbVie's HCV Combo Favorable in Japanese Phase III Study Jan 10 2017
Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal Jan 10 2017
Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal Jan 10 2017
The Best DRIP Stocks: 15 No-Fee Dividend Aristocrats Jan 09 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)